STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

Kemas kini terakhir: 09 Nov, 4:38AM

26.55

-0.08 (-0.30%)

Penutupan Terdahulu 26.63
Buka 26.41
Jumlah Dagangan 1,941,757
Purata Dagangan (3B) 1,008,445
Modal Pasaran 1,310,665,984
Harga / Pendapatan (P/E Ke hadapan) 69.44
Harga / Jualan (P/S) 5.65
Harga / Buku (P/B) 3.68
Julat 52 Minggu
13.50 (-49%) — 30.88 (16%)
Tarikh Pendapatan 5 Nov 2025
Margin Keuntungan -25.46%
Margin Operasi (TTM) -81.43%
EPS Cair (TTM) -1.44
Pertumbuhan Hasil Suku Tahunan (YOY) -44.90%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 107.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 10.48%
Nisbah Semasa (MRQ) 4.78
Aliran Tunai Operasi (OCF TTM) -11.69 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 10.73 M
Pulangan Atas Aset (ROA TTM) -5.90%
Pulangan Atas Ekuiti (ROE TTM) -19.14%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Menaik Bercampur
Medical Instruments & Supplies (Global) Bercampur Menurun
Stok STAAR Surgical Company Menaik Menurun

AISkor Stockmoo

0.7
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam 4.0
Volatiliti Harga -4.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata 0.70

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
STAA 1 B - - 3.68
MMSI 5 B - 44.30 3.39
LMAT 2 B 0.91% 38.12 4.96
ATRC 2 B - - 3.77
AZTA 2 B - 70.58 0.930
PLSE 887 M - - 10.01

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 0.64%
% Dimiliki oleh Institusi 109.43%

Pemilikan

Nama Tarikh Syer Dipegang
Defender Capital, Llc. 30 Sep 2025 701,277

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
02 Dec 2025 Pengumuman Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
10 Nov 2025 Pengumuman Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 Pengumuman STAAR Surgical Announces Amendments to Alcon Merger Agreement
06 Nov 2025 Pengumuman Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
05 Nov 2025 Pengumuman STAAR Surgical Reports Third Quarter 2025 Results
04 Nov 2025 Pengumuman Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
04 Nov 2025 Pengumuman Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
31 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
27 Oct 2025 Pengumuman STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
24 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
24 Oct 2025 Pengumuman Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
23 Oct 2025 Pengumuman Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
22 Oct 2025 Pengumuman Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors
20 Oct 2025 Pengumuman Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
20 Oct 2025 Pengumuman STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
20 Oct 2025 Pengumuman Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
17 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
16 Oct 2025 Pengumuman STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
15 Oct 2025 Pengumuman Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
14 Oct 2025 Pengumuman Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
10 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
08 Oct 2025 Pengumuman Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
08 Oct 2025 Pengumuman STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
08 Oct 2025 Pengumuman Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
07 Oct 2025 Pengumuman Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
06 Oct 2025 Pengumuman Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
06 Oct 2025 Pengumuman STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
06 Oct 2025 Pengumuman STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
06 Oct 2025 Pengumuman Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
03 Oct 2025 Pengumuman Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
30 Sep 2025 Pengumuman Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
26 Sep 2025 Pengumuman STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
24 Sep 2025 Pengumuman Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
22 Sep 2025 Pengumuman STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
22 Sep 2025 Pengumuman Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
16 Sep 2025 Pengumuman STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda